Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 5/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387735 | 0.86 | HDAC6 (0.61) | HDAC6HDAC2HDAC8CLK1CLK2 | |
| SCHEMBL17816224 | 0.84 | LMNA (0.48) | HDAC6CLK1CLK2HDAC1SMN1; SMN2 | |
| SCHEMBL3550941 | 0.84 | BAZ2B (0.51) | BAZ2BGRM5CA2HDAC6HDAC2 | |
| SCHEMBL20224123 | 0.81 | GRM5 (0.51) | GRM5CLK1CLK2HPGDTP53 | |
| SCHEMBL15215455 | 0.81 | CA12 (0.46) | HDAC6CLK1CLK2EPHX2NR1H4 | |
| SCHEMBL24426198 | 0.80 | KDM4E (0.42) | CA2HDAC6CLK1CLK2EPHX2 | |
| SCHEMBL5366444 | 0.79 | KCNJ1 (0.44) | CLK1CLK2EPHX2NR1H4SMN1; SMN2 | |
| SCHEMBL1070876 | 0.79 | P4HA1 (0.55) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL17688886 | 0.79 | HPGDS (0.50) | GRM5SMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL20249181 | 0.79 | MMP13 (0.49) | CA2CLK1CLK2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | BAZ2B 3679/4885GRM5 1553/4885CA2 1829/4885 |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | BAZ2B 711/4885GRM5 2720/4885CA2 4405/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | BAZ2B 1695/4885GRM5 1520/4885CA2 1762/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | BAZ2B 1305/4885GRM5 1799/4885CA2 2400/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | BAZ2B 2932/4885GRM5 3504/4885CA2 1235/4885 |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | DCK, TK1, DTYMK | BAZ2B 890/4885GRM5 2705/4885CA2 4283/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | BAZ2B 1695/4885GRM5 1520/4885CA2 1762/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | BAZ2B 2932/4885GRM5 3504/4885CA2 1235/4885 |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | BAZ2B 890/4885GRM5 2705/4885CA2 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.